Clinical Roundup Phase III trial of zanidatamab in biliary tract cancers produces positive topline data January 06, 2023Vol.49 No.01
Clinical Roundup Oral paclitaxel combination shows positive results for TNBC subgroup in phase II study January 06, 2023Vol.49 No.01
Clinical Roundup UTSW-led study shows promise for upper urinary tract cancer drug January 06, 2023Vol.49 No.01
Clinical Roundup UTSW immunologists uncover obesity-linked trigger to severe form of liver disease January 06, 2023Vol.49 No.01
Clinical Roundup Interim results from OPTIMIZE-1 phase II study show >50% ORR in pancreatic cancer January 06, 2023Vol.49 No.01
Clinical Roundup IU research points to a biomarker for cardiotoxicity in breast cancer–and a role for dexamethasone January 06, 2023Vol.49 No.01
Clinical Roundup Johns Hopkins study identifies gene mechanism in most aggressive kidney cancers January 06, 2023
Clinical Roundup Imbruvica + venetoclax demonstrates efficacy and sustained response in older patients with previously untreated CLL December 16, 2022Vol.48 No.45
Clinical Roundup Phase III study shows long-term results of Darzalex-based regimen in newly diagnosed, transplant-ineligible MM December 16, 2022Vol.48 No.45
Clinical Roundup Phase II data on Regeneron’s linvoseltamab show clinically meaningful responses in heavily pre-treated MM December 16, 2022Vol.48 No.45
